Latest Reimbursement News

Adherium reports a near tenfold surge in recurring revenue from remote patient monitoring and clinical evidence supporting significant cost reductions in respiratory care.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

PolyNovo has delivered solid FY26 revenue growth of 16.1%, driven by commercial sales expansion and improved manufacturing output, while progressing insurance recovery from its R&D centre fire.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Riedel Resources has completed the acquisition of majority interests in the Cosmo and Mt Venn gold projects in the Laverton Gold District, expanding its portfolio to three exploration-stage assets across two Tier 1 jurisdictions.

Sarama Resources has offloaded its Western Australian gold projects to Riedel Resources for A$3.2 million in cash and shares, securing a substantial equity stake and executive influence in the buyer while limiting shareholder dilution amid its arbitration claim.

OncoSil Medical has gained Saudi FDA approval for its OncoSil™ device, enabling full reimbursement and commercial access in Saudi Arabia, the Middle East's largest healthcare market.

True North Copper (ASX:TNC) has agreed to sell its Bundarra Copper Project to Tec Minerals, securing A$500,000 cash, A$1 million equity in Tec Minerals, and a 1% Net Smelter Royalty, as it sharpens focus on its Mt Oxide and Cloncurry copper developments.

Barramundi’s portfolio returned a solid 3.8% gross gain in Q2 2026, driven by strong AI-related infrastructure plays and takeover interest in key holdings, despite sector volatility and profit downgrades in healthcare and logistics.

Phoslock Environmental Technologies increased production significantly in the June quarter but faced a higher operating cash flow deficit and ongoing legal disputes.

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.

Pacific Edge edges closer to Medicare reimbursement for its bladder cancer tests while its Asia Pacific operations show rising test volumes and improved margins, signaling a path toward profitability.